BofA upgraded Quest Diagnostics to Buy from Neutral with a price target of $160, up from $140. National clinical labs face fewer headwinds in 2024 than most of the broader Tools, Diagnostics, and Biopharma Services companies, Covid-related headwinds have dissipated, and the base business is executing consistently, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- WHO ‘worried’ about mpox spread in DRC, Reuters reports
- CDC issues health advisory for subtype of mpox virus in Congo
- Quest Diagnostics and CDC expand hepatitis research collaboration
- Quest Diagnostics and Scipher Medicine collaborate in rheumatoid arhritis
- Quest Diagnostics partners with Universal DX for colorectal cancer blood test